Prothena Q1 2025 Earnings Report

Prothena EPS Results

• Actual EPS: -$1.12
• Consensus EPS: -$0.92
• Beat/Miss: Missed by -$0.20
• One Year Ago EPS: -$1.34

Prothena Revenue Results

• Actual Revenue: $2.83 million
• Expected Revenue: $8.18 million
• Beat/Miss: Missed by -$5.35 million
• YoY Revenue Growth: +5,500.00%

Prothena Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: After Market Closes
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 4:00PM ET

Prothena (NASDAQ:PRTA) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials. Additional pipeline candidates include therapies for amyloid light chain (AL) amyloidosis and other protein misfolding disorders. Prothena collaborates with global pharmaceutical partners to further develop and commercialize its product candidates, pooling resources and expertise to accelerate research timelines.

Founded in 2012 as a spin-out from Elan Corporation, Prothena is headquartered in South San Francisco, California, with research operations in both the United States and Ireland. The company maintains a global focus, engaging regulators and trial sites across North America, Europe and Asia to support its clinical development programs. Prothena’s commitment to addressing high-unmet-need diseases is reflected in its strategic partnerships and research investments.

Prothena is led by President and Chief Executive Officer Gene Kinney, whose experience spans decades in the pharmaceutical and biotechnology sectors. Under his leadership, the company has built a multidisciplinary team of scientists, clinicians and commercial experts. Prothena’s board and management team bring deep expertise in protein science, immunology and drug development to guide the company’s mission of bringing new treatment options to patients worldwide.